Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Maintains Strong Position in Biotech Sector

Font: Financial Modeling Prep  • Mar 09, 2026

• Cowen & Co. reiterates a "Buy" rating for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), indicating confidence in the company's future performance.
• Regeneron showcases its latest developments at the TD Cowen 46th Annual Health Care Conference, highlighting its innovative approach to drug development.
• The stock price of Regeneron has seen a slight increase, with a current price of $768.64, reflecting positive market sentiment.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biotechnology company known for its innovative approach to drug development. The company focuses on developing medicines for serious diseases, including eye diseases, cancer, and allergic conditions. Regeneron competes with other major pharmaceutical companies like Amgen and Biogen in the biotechnology sector.

On March 9, 2026, Cowen & Co. reiterated its "Buy" rating for Regeneron, with the stock priced at $764.11. This rating suggests confidence in the company's future performance. At the time, the recommendation was to hold the current position, indicating that investors should maintain their investment in the stock.

Recently, Regeneron participated in the TD Cowen 46th Annual Health Care Conference, a significant event in the healthcare sector. This conference allowed Regeneron to showcase its latest developments and strategies, attracting attention from key players and stakeholders. Such events are crucial for companies to communicate their progress and future plans to investors and industry experts.

The stock price for Regeneron has seen a slight increase, currently priced at $768.64, up by approximately 1.15% from the previous session. This rise of $8.78 indicates positive market sentiment following the company's participation in the conference. The stock has fluctuated between a low of $753.74 and a high of $770.25 today, showing some volatility in trading.

Regeneron's market capitalization stands at approximately $79.86 billion, reflecting its significant presence in the biotechnology industry. The trading volume for the day is 132,758 shares, indicating active investor interest. Over the past year, the stock has experienced a high of $821.11 and a low of $476.49, showcasing its potential for growth and resilience in the market.